Younger DCIS Patients Face Higher Recurrence Risk After Breast-Conserving Surgery

Article

Following breast-conserving surgery for ductal carcinoma in situ (DCIS), younger women face a higher risk than older patients for recurrence of both DCIS and invasive carcinomas.

Following breast-conserving surgery (BCS) for ductal carcinoma in situ (DCIS), younger women face a higher risk than older patients for recurrence of both DCIS and invasive carcinomas, reported Kimberly Van Zee, MD, FACS, a surgical oncologist at Memorial Sloan Kettering Cancer Center in New York, at the 33rd Annual Miami Breast Cancer Conference, held March 10–13 in Miami Beach, Florida.

“Young age (younger than age 40 years at diagnosis) is a highly significant risk factor for any recurrence after BCS for DCIS,” Dr. Van Zee said, during her review of the available research.

Ten-year recurrence rates of 27.3% for women younger than 40 vs 7.5% among women 80 or older,” she said. “This age effect persists even after adjusting for other factors that vary by age.”

“Older age was associated with lower recurrence in both cohorts that did and did not receive radiation,” she added.

Women younger than 40 years face a seven-fold higher risk of invasive recurrence than do women age 80 or older at the time of DCIS diagnosis.

“In women younger than 40 years, invasive recurrences are more likely than DCIS recurrences,” she noted, whereas DCIS recurrences are more common in women age 40 or older.

“Age is an important factor that should be considered in weighing the various treatment options, including surgical options and the use of adjuvant radiation and endocrine therapies,” Dr. Van Zee said. “Women age 80 or older are at low risk of recurrence, even in the absence of adjuvant therapies.”

Recent Videos
Preliminary phase 2 trial data show durvalumab plus lenalidomide was superior to durvalumab alone in refractory/advanced cutaneous T-cell lymphoma.
Performance status, age, and comorbidities may impact benefit seen with immunotherapy vs chemotherapy in patients with breast cancer.
Developing odronextamab combinations following CAR T-cell therapy failure may help elicit responses in patients with diffuse large B-cell lymphoma.
Cytokine release syndrome was primarily low or intermediate in severity, with no grade 5 instances reported among those with diffuse large B-cell lymphoma.
Safety results from a phase 2 trial show that most toxicities with durvalumab treatment were manageable and low or intermediate in severity.
Updated results from the 1b/2 ELEVATE study elucidate synergizing effects observed with elacestrant plus targeted therapies in ER+/HER2– breast cancer.
Patients with ESR1+, ER+/HER2– breast cancer resistant to chemotherapy may benefit from combination therapy with elacestrant.
Related Content